Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Caprylic Triglyceride Formulations (AC-1202, AC-1204, Axona)
NCT02833012Phase 1Completed
- Sponsor
- Cerecin
- Start
- Jul 2016
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tricaprilin in Alzheimer's disease (AD) (4 arms), sponsored by Cerecin. Primary endpoints: Total Ketones Area Under the Curve from time 0 to last measurable concentration, Total Ketones Maximum Observed Concentration and 4 more. Started Jul 2016; status: completed.
02
Drugs
tricaprilin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02833012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833012.